Pelthos Therapeutics Inc.

AMEX: PTHS · Healthcare · Biotechnology

PublicHQ Durham, NC · DurhamCIK 0001919246Reports USD

#568 of 1,394 Healthcare companies by revenue

EA Score

35D

FH 47DQ 21GM —SS 22

v0.1 · 55/100 weight · provisional

↑ Piotroski F, Altman-Z · ↓ disclosure history, listing tenure

Methodology →

Revenue TTM

$27.7M

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$43.3M

Employees

Market cap

$16.7M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$16.8M$16.8M2025

Net income-$43.3M-$43.3M2025

Operating income-$32.4M-$32.4M2025

Total assets$130.4M$130.4M2025

Liabilities$91.5M$91.5M2025

Equity$38.9M$38.9M2025

Revenue by segment

Filed disclosures · FY2025

By product

License and Collaboration100%

By geography

Not disclosed.

The read

Pelthos Therapeutics Inc. booked $16.8M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -257.9% net margin.

Peers · Healthcare

Werewolf Therapeutics, Inc.——Voyageur Pharmaceuticals Ltd.——Selectis Health, Inc.61C Zenith Capital Corp.——

Neighbors

Durham →

IQVIA Holdings Inc.$16.3B80B+Wolfspeed Inc.$757.6M43D BioCryst Pharmaceuticals, Inc.$874.8M76B+Fortrea Holdings Inc.$2.7B50D Bioventus Inc.$568.1M66B NET Power Inc.$029D

Key facts

CEOScott Plesha

SectorHealthcare

IndustryBiotechnology

HeadquartersDurham, NC

ExchangeAMEX: PTHS

Employees4

IPO date2025-07-02

Latest filings

8-K2026-05-28 8-K2026-05-21 8-K2026-05-14 10-Q2026-05-14 8-K2026-04-14 8-K2026-04-10 10-K2026-03-19 8-K2026-03-19

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.